Abstract

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Randomized Clinical Trials-Cost-Effectiveness Analysis (RCTCEA) task force report contains a comprehensive discussion of the methodological issues arising in conducting economic evaluations alongside clinical trials. The report is intended to be relevant to all trials, from exploratory (efficacy) studies to pragmatic (effectiveness) studies, although the authors acknowledge that the former studies are in the majority.